

**International consensus is needed on a core outcome set to advance the evidence of best practice in cancer prehabilitation services and research.**

MYERS, Anna <<http://orcid.org/0000-0001-6432-8628>>, BARLOW, Rachel, BALDINI, Gabriele, CAMPBELL, Anna, CARLI, Franco, CARR, Esther, COLLYER, Tom, DANJOUX, Gerard, DAVIS, June, DENEHY, Linda, DURRAND, James, GILLIS, Chelsia, GREENFIELD, Diana, GRIFFITHS, Stuart, GROCOTT, Mike, HUMPHREYS, Liam <<http://orcid.org/0000-0002-9279-1019>>, JACK, Sandy, KEEN, Carol, LEVETT, Denny, MERCHANT, Zoe, MOORE, John, MOUG, Susan, RICKETTS, William, SANTA MINA, Daniel, SAXTON, John, SHAW, Clare, TEW, Garry, THELWELL, Michael, WEST, Malcolm and COPELAND, Robert <<http://orcid.org/0000-0002-4147-5876>>

Available from Sheffield Hallam University Research Archive (SHURA) at:

<http://shura.shu.ac.uk/33407/>

---

This document is the author deposited version. You are advised to consult the publisher's version if you wish to cite from it.

**Published version**

MYERS, Anna, BARLOW, Rachel, BALDINI, Gabriele, CAMPBELL, Anna, CARLI, Franco, CARR, Esther, COLLYER, Tom, DANJOUX, Gerard, DAVIS, June, DENEHY, Linda, DURRAND, James, GILLIS, Chelsia, GREENFIELD, Diana, GRIFFITHS, Stuart, GROCOTT, Mike, HUMPHREYS, Liam, JACK, Sandy, KEEN, Carol, LEVETT, Denny, MERCHANT, Zoe, MOORE, John, MOUG, Susan, RICKETTS, William, SANTA MINA, Daniel, SAXTON, John, SHAW, Clare, TEW, Garry, THELWELL, Michael, WEST, Malcolm and COPELAND, Robert (2024). International consensus is needed on a core outcome set to advance the evidence of best practice in cancer prehabilitation services and research. *British Journal of Anaesthesia*.

---

**Copyright and re-use policy**

Sheffield Hallam University Research Archive

<http://shura.shu.ac.uk>

See <http://shura.shu.ac.uk/information.html>

1 **International consensus is needed on a core outcome set to advance the evidence of best practice**  
2 **in cancer prehabilitation services and research**

3 \*Anna M Myers,<sup>1</sup> Rachael C Barlow,<sup>2</sup> Gabriele Baldini,<sup>3</sup> Anna M Campbell,<sup>4</sup> Franco Carli,<sup>5</sup> Esther J  
4 Carr,<sup>6</sup> Tom Collyer,<sup>7</sup> Gerard Danjoux,<sup>8</sup> June F Davis,<sup>9</sup> Linda Denehy,<sup>10</sup> James Durrand,<sup>11</sup> Chelsia Gillis,<sup>12</sup>  
5 Diana M Greenfield,<sup>13</sup> Stuart P Griffiths,<sup>14</sup> Mike Grocott,<sup>15</sup> Liam Humphreys,<sup>16</sup> Sandy Jack,<sup>17</sup> Carol  
6 Keen,<sup>18</sup> Denny Z H Levett,<sup>19</sup> Zoe Merchant,<sup>20</sup> John Moore,<sup>21</sup> Susan Moug,<sup>22</sup> William Ricketts,<sup>23</sup> Daniel  
7 Santa Mina,<sup>24</sup> John M Saxton,<sup>25</sup> Clare E Shaw,<sup>26</sup> Garry A Tew,<sup>27</sup> Michael Thelwell,<sup>28</sup> Malcolm A West,<sup>29</sup>  
8 & Robert J Copeland<sup>30</sup>

9

10 **Keywords**

11 Prehabilitation, Rehabilitation, Cancer, Surgery, Core Outcome Set

12

13 <sup>1</sup> Advanced Wellbeing Research Centre, Sheffield Hallam University, Olympic Legacy Park, 2 Old Hall

14 Road, Sheffield, S9 3TU, United Kingdom; Email - [A.Myers@shu.ac.uk](mailto:A.Myers@shu.ac.uk); Twitter - @Anna\_Myers1

15 (\*corresponding author)

16 <sup>2</sup> Cardiff and Vale University Health Board, University Hospital of Wales, Heath Park, Cardiff

17 CF145XW, United Kingdom; Email - [Rachael.barlow2@wales.nhs.uk](mailto:Rachael.barlow2@wales.nhs.uk)

18 <sup>3</sup> Anaesthesiology and Intensive Care Department of Health Sciences, Section of Anaesthesiology,

19 Intensive Care and Pain Medicine, University of Florence, Florence, Italy; Email -

20 [gabriele.baldini@unifi.it](mailto:gabriele.baldini@unifi.it)

21 <sup>4</sup> Edinburgh Napier University, Sighthill, Edinburgh, EH11 4BN, United Kingdom; Email -

22 [A.Campbell4@napier.ac.uk](mailto:A.Campbell4@napier.ac.uk); Twitter - @Canrehab

23 <sup>5</sup> Department of Anaesthesia, McGill University Health Center, Glen Site, Royal Victoria Hospital 1001  
24 boul. Montreal, Canada, H4A 3J1; Email - [franco.carli@mcgill.ca](mailto:franco.carli@mcgill.ca)

25 <sup>6</sup> South Tees NHS Foundation Trust, James Cook University Hospital, Marton Road, Middlesbrough,  
26 United Kingdom; Email - [esther.carr@nhs.net](mailto:esther.carr@nhs.net)

27 <sup>7</sup> Anaesthetic Department, Harrogate and District NHS Foundation Trust, Lancaster Park Road,  
28 Harrogate, North Yorkshire, HG2 7SX, United Kingdom; Email - [thomas.collyer@nhs.net](mailto:thomas.collyer@nhs.net)

29 <sup>8</sup> North Yorkshire Academic Alliance of Perioperative Medicine, James Cook University Hospital,  
30 Middlesbrough, TS4 3BW, United Kingdom; Email - [gerard.danjoux@nhs.net](mailto:gerard.danjoux@nhs.net)

31 <sup>9</sup> Macmillan Cancer Support, 89 Albert Embankment, Vauxhall, London, SE1 7UQ; and Allied Health  
32 Solutions, The Stables, Goblands Farm Business Centre, Hadlow, Kent, TN11 0LT, United Kingdom;  
33 Email - [jfdavis@macmillan.org.uk](mailto:jfdavis@macmillan.org.uk); Twitter - @Junedavis44

34 <sup>10</sup> Department of Physiotherapy, The University of Melbourne, Parkville 3010, Melbourne, Australia;  
35 and Peter MacCallum Cancer Centre, 300 Grattan Street, Carlton 3000, Melbourne, Australia; Email:  
36 [l.denehy@unimelb.edu.au](mailto:l.denehy@unimelb.edu.au); Twitter - @LindaDenehy

37 <sup>11</sup> Department of Anaesthesia and Perioperative Medicine, James Cook University Hospital, Marton  
38 Road, Middlesbrough, TS4 3BW, United Kingdom; Email - [jdurrand@doctors.org.uk](mailto:jdurrand@doctors.org.uk)

39 <sup>12</sup> School of Human Nutrition, McGill University, Montreal, Canada; Email - [chelsia.gillis@mcgill.ca](mailto:chelsia.gillis@mcgill.ca)

40 <sup>13</sup> Weston Park Hospital, Sheffield Teaching Hospitals NHS Foundation Trust, Whitham Road,  
41 Sheffield, S10 2SJ, United Kingdom; Email - [diana.greenfield@nhs.net](mailto:diana.greenfield@nhs.net)

42 <sup>14</sup> Yorkshire Cancer Research, Jacob Smith House, 7 Grove Park Court, Harrogate, HG1 4DP, United  
43 Kingdom; Email - [Stuart.griffiths@ycr.org.uk](mailto:Stuart.griffiths@ycr.org.uk)

44 <sup>15</sup> Faculty of Medicine, University of Southampton, Southampton, United Kingdom; and Acute  
45 Perioperative and Critical Care Theme, NIHR Southampton Biomedical Research Centre, University

46 Hospital Southampton NHS Trust, University of Southampton, Southampton, United Kingdom; Email  
47 - [mike.grocott@soton.ac.uk](mailto:mike.grocott@soton.ac.uk)

48 <sup>16</sup> Advanced Wellbeing Research Centre, Sheffield Hallam University, Olympic Legacy Park, 2 Old Hall  
49 Road, Sheffield, S9 3TU, United Kingdom; Email - [I.humphreys@shu.ac.uk](mailto:I.humphreys@shu.ac.uk)

50 <sup>17</sup> Faculty of Medicine, University of Southampton, Southampton, United Kingdom; and NIHR  
51 Biomedical Research Centre, University Hospital Southampton NHS Trusts, Southampton, United  
52 Kingdom; Email - [S.Jack@soton.ac.uk](mailto:S.Jack@soton.ac.uk)

53 <sup>18</sup> Sheffield Teaching Hospitals NHS Foundation Trust, Glossop Road, Sheffield, S10 2JF, United  
54 Kingdom; Email - [carol.keen@nhs.net](mailto:carol.keen@nhs.net)

55 <sup>19</sup> Perioperative and Critical Care Theme, NIHR Southampton Biomedical Research Centre, University  
56 Hospital Southampton/University of Southampton, Tremona Road, Southampton, SO16 6YD, United  
57 Kingdom; Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences,  
58 Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Email -  
59 [D.Levett@soton.ac.uk](mailto:D.Levett@soton.ac.uk)

60 <sup>20</sup> Greater Manchester Cancer Alliance, c/o The Christie NHS Foundation Trust, 2nd floor, PTB Cabin,  
61 Wilmslow Road, Manchester, M20 4BX, United Kingdom; Email - [Zoe.merchant@nhs.net](mailto:Zoe.merchant@nhs.net); Twitter -  
62 @prehab4Cancer @zoemerchantOT

63 <sup>21</sup> Department of Anaesthesia and Peri-operative Medicine 5th Floor, Manchester University NHS  
64 Foundation Trust, Oxford Road, Manchester, M13 9XL, United Kingdom; Email -  
65 [john.moore@mft.nhs.uk](mailto:john.moore@mft.nhs.uk)

66 <sup>22</sup> Departments of Colorectal Surgery, Royal Alexandra Hospital, Corsebar Road, Paisley, Scotland,  
67 PA2 9PN, United Kingdom; Email - [Susan.moug@ggc.scot.nhs.uk](mailto:Susan.moug@ggc.scot.nhs.uk); Twitter - @susanmoug

68 <sup>23</sup> Respiratory Medicine, Barts Health NHS Trust, St Bartholomew's Hospital, West Smithfield, London  
69 EC1A 7BE, United Kingdom; Email - [William.Ricketts@nhs.net](mailto:William.Ricketts@nhs.net)

70 <sup>24</sup> Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada,  
71 M5S 2W6; and Department of Anaesthesiology and Pain Management, University Health Network,  
72 Toronto, Ontario, Canada, M5G 2C4; Email - [Daniel.santamina@utoronto.ca](mailto:Daniel.santamina@utoronto.ca); Twitter -  
73 @DR\_SantaMina

74 <sup>25</sup> School of Sport, Exercise and Rehabilitation Sciences, University of Hull, Hull, United Kingdom;  
75 Email - [John.Saxton@hull.ac.uk](mailto:John.Saxton@hull.ac.uk)

76 <sup>26</sup> NIHR Biomedical Research Centre at The Royal Marsden and the Institute of Cancer Research,  
77 London, United Kingdom; Email - [Clare.Shaw@rmh.nhs.uk](mailto:Clare.Shaw@rmh.nhs.uk)

78 <sup>27</sup> York St John University, Lord Mayor's Walk, York, YO31 7EX, United Kingdom; Email -  
79 [g.tew@yorks.ac.uk](mailto:g.tew@yorks.ac.uk)

80 <sup>28</sup> Advanced Wellbeing Research Centre, Sheffield Hallam University, Olympic Legacy Park, 2 Old Hall  
81 Road, Sheffield, S9 3TU, United Kingdom; Email - [m.thelwell@shu.ac.uk](mailto:m.thelwell@shu.ac.uk)

82 <sup>29</sup> University of Southampton, Faculty of Medicine, Cancer Sciences, University Surgery, Room AC67  
83 Mail Point 816, Level C, South Academic Block, Southampton University Hospital NHS Foundation  
84 Trust, Tremona Road, Southampton, Hampshire, SO16 6YD, United Kingdom; Email -  
85 [m.west@soton.ac.uk](mailto:m.west@soton.ac.uk)

86 <sup>30</sup> Advanced Wellbeing Research Centre, Sheffield Hallam University, Olympic Legacy Park, 2 Old Hall  
87 Road, Sheffield, S9 3TU, United Kingdom; Email - [R.J.Copeland@shu.ac.uk](mailto:R.J.Copeland@shu.ac.uk); Twitter -  
88 @DrRobCopeland

89

90

91

92

93 **Abstract**

94 Prehabilitation aims to optimise patients' physical and psychological status before treatment. The  
95 types of outcomes measured to assess the impact of prehabilitation interventions vary across clinical  
96 research and service evaluation, limiting the ability to compare between studies and services and to  
97 pool data. An international workshop involving academic and clinical experts in cancer  
98 prehabilitation was convened in May 2022 at Sheffield Hallam University's Advanced Wellbeing  
99 Research Centre, England. The workshop substantiated calls for a core outcome set to advance  
100 knowledge and understanding of best practice in cancer prehabilitation and to develop national and  
101 international databases to assess outcomes at a population level.

102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114

## 115 **Background**

116 In 2020, there were an estimated 18.1 million new cancer cases globally; of those, 51% were cases in  
117 men and 49% were in women.<sup>1</sup> People undergoing treatment (including surgery, chemotherapy, and  
118 radiotherapy) for cancer may experience, or be at risk of, adverse effects, particularly those who are  
119 ‘high-risk’ (such as those who are deconditioned or experiencing frailty) or who do not possess  
120 sufficient physiological resilience to tolerate treatment well. For example, in England, approximately  
121 45% of patients with cancer undergo surgical procedures<sup>2</sup> and, depending on the type of surgery,  
122 10% to 56% of patients develop postoperative complications that delay discharge.<sup>3</sup> A range of  
123 factors contribute to the risk of complications including age, multiple comorbidities, frailty, poor  
124 aerobic fitness, and lifestyle factors such as physical inactivity, malnutrition, and smoking.  
125 Treatment-related complications inflate costs (longer hospital length of stay [LOS]), more medical  
126 interventions and increased readmissions), and vastly worsen patient experiences.<sup>4</sup> This is  
127 unsurprising given the physiological and psychological stress related to surgery<sup>5</sup> and the lack of  
128 physiological and psychological resilience in high-risk groups.<sup>4</sup> In the context of cancer care,  
129 prehabilitation is *“a process on the cancer continuum of care that occurs between the time of cancer  
130 diagnosis and the beginning of acute treatment and includes physical and psychological assessments  
131 that establish a baseline function level, identify impairments, and provide interventions that promote  
132 physical and psychological health to reduce the incidence and/or severity of future impairments”*.<sup>6</sup>  
133 Over the last 5-10 years, the number of cancer prehabilitation studies and services has significantly  
134 increased. A search of the NCBI PubMed database for search terms “cancer prehabilitation”  
135 returned 17 items published in 2010 and 206 items published in 2020. Many of these studies have  
136 tested interventions aimed at modifying risk factors associated with poorer surgical outcomes in the  
137 preoperative period and, more recently, for patients undergoing non-surgical cancer treatments.<sup>7-9</sup>  
138 The Macmillan Principles and Guidance for Prehabilitation within the Management and Support of  
139 People with Cancer report highlights the need to develop and consistently employ a range of



140 standardised screening, assessment, adherence, efficacy, experience, and outcome measures.<sup>10</sup> The  
141 most commonly reported outcomes in the prehabilitation literature relate to clinical (e.g.,  
142 postoperative complications) and functional (e.g., aerobic capacity) endpoints.<sup>11</sup> However, the  
143 specific outcomes measured, the methods and tools used to capture them, and the timepoints at  
144 which they are captured vary across studies and services.<sup>10, 12-14</sup> Consequently, impact of  
145 prehabilitation for people with cancer is not well understood, and comparison between studies and  
146 services is limited.

147 Prospective RCTs of prehabilitation have been conducted, although most are small and selective,  
148 and the certainty of evidence varies across outcomes, cancer, and treatment types. Results from  
149 meta-analyses are promising with evidence that prehabilitation improves surrogate measures of  
150 fitness (e.g. functional capacity) but have shown inconsistency in patient-reported outcomes.

151 Prehabilitation also has the potential to increase the range of treatment options available to patients  
152 who would not otherwise be suitable candidates.<sup>6</sup> A recent umbrella review of 55 systematic reviews  
153 of prehabilitation interventions, including nutrition, exercise, and psychological strategies, identified,  
154 with moderate certainty evidence, that prehabilitation improved functional recovery, and low  
155 certainty evidence suggested that prehabilitation supported reductions in complications, non-home  
156 discharge, and length of stay.<sup>15</sup> Included studies showed considerable heterogeneity in study  
157 outcomes, cautioning the strength of study findings. The prehabilitation community is yet to define  
158 the most appropriate outcomes to measure to demonstrate the impact of prehabilitation and this is  
159 perhaps a reflection of the relative infancy of the field. The outcomes also need to be relevant and  
160 important to a wide variety of stakeholders including patients and the public, health care  
161 professionals and others making commissioning/funding decisions about health care if the findings  
162 are to influence policy and practice.

163 The COMET (Core Outcome Measures in Effectiveness Trials) initiative supports investigators in  
164 developing and applying agreed standardised sets of outcomes, known as a “core outcome set”

165 (COS). COS is defined as “An agreed, standardised set of outcomes that should be measured and  
166 reported, as a minimum, in all clinical research in specific areas of health or health care”.<sup>16</sup> A search  
167 of the COMET Initiative database for prehabilitation COS studies returned only two study protocols;  
168 one specific to intra-abdominal cancer (study ongoing)<sup>17</sup> and another focused on colorectal surgery  
169 (study complete - pending publication).<sup>18</sup> Although the results of these studies will be helpful, some  
170 measures may not be applicable to studies and services that include a broad range of cancer types  
171 and treatment options. A standard set of outcome measures that should be reported, as a minimum,  
172 across all cancer prehabilitation research studies and service delivery (including all types of cancer  
173 treatment) will enable researchers and healthcare professionals to compare and contrast different  
174 delivery models and combine datasets with a view to assessing the impact of prehabilitation  
175 interventions and services on cancer outcomes at a population level.

#### 176 **International cancer prehabilitation outcomes workshop**

177 On the 27<sup>th</sup> of May 2022, an international workshop was convened at Sheffield Hallam University’s  
178 Advanced Wellbeing Research Centre in Sheffield, England. The workshop invitation was distributed  
179 through the workshop organising committees prehabilitation networks. Academic and clinical  
180 experts in cancer prehabilitation attended in-person or virtually from across the United Kingdom,  
181 Australia, Canada, and Italy. The workshop explored current practice as well as future directions and  
182 opportunities for outcome data collection in prehabilitation research and service evaluation. The  
183 purpose of the workshop was to discuss and pursue consensus on a core outcome data set for  
184 prehabilitation trials and services to enhance the quality and comparability of prehabilitation studies  
185 in cancer. To inform discussion on the day, delegates were asked to provide the outcomes they are  
186 currently capturing in their research or service evaluations. This information was collated and  
187 presented back to the group on the day. Additionally, cancer prehabilitation groups from each  
188 country were invited to present current practice and research pertaining to core outcomes in  
189 prehabilitation. The day ended with a roundtable discussion about current state-of-the-art outcome

190 data capture in prehabilitation, current gaps and inconsistencies and next steps toward a core  
191 outcome set for prehabilitation research and service evaluation.

192 **Summary of current outcomes being captured by prehabilitation groups attending the workshop**

193 Ten prehabilitation groups provided information about the reporting characteristics and outcomes  
194 being captured in their research and service evaluation. Data were grouped into five domains:  
195 baseline characteristics, medical history and screening, objective (physical or physiological)  
196 measures, self-report (psychological and behavioural) measures, and medical record data (Table 1).  
197 There was inconsistency across groups in the outcomes being captured and the frequency with  
198 which they are assessed. Where there was consistency in the type of outcome being captured, the  
199 tools and tests used to capture them varied. For example, aerobic capacity was measured by all ten  
200 groups. However, one was using cardiopulmonary exercise testing (CPET), two were using the 6-  
201 minute walk test (6MWT), and seven were using both CPET and 6MWT. Where CPETs were being  
202 conducted, this was not routine across participants and depended on whether clinical teams were  
203 using it to assess suitability for surgery.

204 Variability in self-report measures was even more apparent, partially driven by choice between  
205 questionnaires which capture the same or very similar outcomes. For example, self-reported  
206 physical activity was assessed by eight groups using five different questionnaires (exercise vital signs,  
207 CHAMPS physical activity questionnaire, Active Lives Survey, Godin Leisure-Time Exercise  
208 Questionnaire (GLTEQ) and the International Physical Activity Questionnaire (IPAQ)). Fatigue was  
209 measured using either the Functional Assessment of Chronic Illness Therapy – Fatigue scale (FACIT-  
210 Fatigue) or the European Organisation for Research and Treatment of Cancer Quality of Life  
211 Questionnaire (EORTC QLQ-C30) fatigue sub-scale, quality of life was assessed using the European  
212 Quality of Life-5 Dimensions-5 Levels (EQ-5D-5L), the EORTC QLQ-C30 or the 12-Item Short Form  
213 Survey (SF12), and anxiety and depression was measured using the Patient Health Questionnaire-9  
214 (PHQ-9), General Anxiety Disorder-7 (GAD-7), Hospital Anxiety and Depression Scale (HADS) and the

215 Major Depression Inventory. Nutritional status was assessed by seven of the groups and three  
216 different tools were used (Patient-Generated Subjective Global Assessment (PG-SGA), modified PG-  
217 SGA (mPG-SGA), Malnutrition Universal Screening Tool (MUST) and Canadian Nutrition Screening  
218 Tool). Most groups were using length of stay, readmissions, and mortality, but there was  
219 inconsistency in how these outcomes were defined. For example, readmissions were classified in  
220 several ways, including being an unplanned inpatient for less than three days/more than three days,  
221 30-day all-cause readmission, and 90-day all-cause readmission.

222

223 \*Table 1 around here\*

224

## 225 **Key priorities**

226 There was general consensus on the constructs that should be measured in prehabilitation research  
227 and evaluation amongst the ten prehabilitation groups who provided information. Despite alignment  
228 on the general areas of evaluation (e.g., physical and psychological health, quality of life, hospital-  
229 related outcomes), these constructs have large variability in how they are measured. The  
230 international stakeholders agreed that developing a core outcome set is a priority to advance our  
231 knowledge and understanding of best practice in cancer prehabilitation. An umbrella review of  
232 systematic reviews also emphasised the need for a core outcome set in this area to develop a robust  
233 evidence base<sup>15</sup> and a recent international Delphi study rated defining prehabilitation core outcome  
234 measures as a top ten research priority.<sup>19</sup> Achieving consistency of outcome reporting across  
235 research studies and services will require international consensus and clear guidance. A natural next  
236 step would be to develop national and international databases to compare and contrast the impact  
237 of different interventions and to assess outcomes at a population level and authors here are  
238 committed to working internationally to deliver this.

239 Additional priorities were highlighted during the workshop. First, the diversity of cancer  
240 prehabilitation interventions was acknowledged and the need to clearly describe the intervention in  
241 line with accepted frameworks (e.g. the Template for Intervention Description and Replication  
242 checklist (TIDieR)<sup>20</sup> and the Consensus on Exercise Reporting Template (CERT)<sup>21</sup>) was emphasised.  
243 Second, once consensus is reached on *what* core prehabilitation outcomes to measure, additional  
244 work is needed to clearly define those measures and *how* and *when* to utilise them. Third, the need  
245 to utilise and adopt new information technology systems to link routinely collected primary and  
246 secondary care data with research and service evaluation data is vital to save time and resource and  
247 demonstrate impact. Importantly, outcomes should be relevant to a wide variety of stakeholders,  
248 including patients and the public, health care professionals and others making commissioning  
249 decisions about health care if the findings are to influence policy and practice. For example, a patient  
250 might be most interested in the potential impact of prehabilitation on postoperative recovery or  
251 quality of life whilst a commissioner might want to know the cost savings associated with  
252 implementing a prehabilitation programme. It is acknowledged that not all cancer prehabilitation  
253 stakeholders were present at the workshop (including patients, commissioners, and oncologists).  
254 Similarly, we acknowledge that not all groups working in prehabilitation were represented and so it  
255 is possible that some perspectives have not been captured. Therefore, the COS consensus process  
256 should endeavour to include a variety of stakeholders to represent different perspectives.

257 In conclusion, cancer prehabilitation has demonstrated its initial and intuitive value with evidence  
258 from small-scale intervention studies. To fully understand the impact that can be made on clinical  
259 endpoints through a multimodal support programme prior to treatment, robustly designed, large-  
260 scale studies that utilise consistent outcomes and tools are essential so that data can be pooled to  
261 increase the confidence in the estimates of effect and ultimately advance clinical practice.

262

263

264 **Authors' contributions**

265 Anna M Myers: Conceptualisation, Methodology, Formal analysis, Investigation, Writing - Original  
266 Draft; Rachael C Barlow, Gabriele Baldini, Anna M Campbell, Franco Carli, Esther J Carr, Tom Collyer,  
267 Gerard Danjoux, June F Davis, Linda Denehy, James Durrand, Chelsia Gillis, Diana M Greenfield,  
268 Stuart P Griffiths, Mike Grocott, Liam Humphreys, Sandy Jack, Carol Keen, Denny Z H Levett, Zoe  
269 Merchant, John Moore, Susan Moug, William Ricketts, Daniel Santa Mina, John M Saxton, Clare E  
270 Shaw, Garry A Tew, Michael Thelwell, Malcolm A West: Writing - Review & Editing; Robert J  
271 Copeland: Conceptualisation, Methodology, Writing - Review & Editing.

272 **Collaborators**

273 We would like to thank Fiona Davey, Maria Pufulete, Stephen Wootton and Victoria Hope who  
274 contributed to discussions during the workshop.

275 **Funding**

276 There was no funding for this project.

277 For the purpose of open access, the author has applied a Creative Commons Attribution (CC BY)  
278 licence to any Author Accepted Manuscript version arising from this submission.

279 **Declaration of interest**

280 The authors declare that they have no known competing financial interests or personal relationships  
281 that could have appeared to influence the work reported in this paper.

282 **References**

283 1 World Cancer Research Fund International. Worldwide cancer data. Available from  
284 [https://www.wcrf.org/cancer-trends/worldwide-cancer-](https://www.wcrf.org/cancer-trends/worldwide-cancer-data/#:~:text=There%20were%20an%20estimated%2018.1%20million%20cancer%20cases,cancers%20globally%20are%20listed%20in%20the%20tables%20below)  
285 [data/#:~:text=There%20were%20an%20estimated%2018.1%20million%20cancer%20cases,cancers%20globally%20are%20listed%20in%20the%20tables%20below](https://www.wcrf.org/cancer-trends/worldwide-cancer-data/#:~:text=There%20were%20an%20estimated%2018.1%20million%20cancer%20cases,cancers%20globally%20are%20listed%20in%20the%20tables%20below). (accessed 16 January 2024)  
286  
287 2 Public Health England. Chemotherapy, Radiotherapy and Surgical Tumour Resections in England.  
288 2020. Available from [https://www.gov.uk/government/statistics/chemotherapy-radiotherapy-and-](https://www.gov.uk/government/statistics/chemotherapy-radiotherapy-and-surgical-tumour-resections-in-england/chemotherapy-radiotherapy-and-surgical-tumour-resections-in-england)  
289 [surgical-tumour-resections-in-england/chemotherapy-radiotherapy-and-surgical-tumour-resections-](https://www.gov.uk/government/statistics/chemotherapy-radiotherapy-and-surgical-tumour-resections-in-england/chemotherapy-radiotherapy-and-surgical-tumour-resections-in-england)  
290 [in-england](https://www.gov.uk/government/statistics/chemotherapy-radiotherapy-and-surgical-tumour-resections-in-england/chemotherapy-radiotherapy-and-surgical-tumour-resections-in-england) (accessed 16 January 2024)

291 3 Nathan H, Atoria CL, Bach PB, Elkin EB. Hospital Volume, Complications, and Cost of Cancer Surgery  
292 in the Elderly. *Journal of Clinical Oncology* 2015; **33**: 107-14

293 4 Durrand J, Singh S, Danjoux G. Prehabilitation. *Clin Med* 2019; **19**: 10.7861

294 5 Helander EM, Webb MP, Menard B, et al. Metabolic and the surgical stress response  
295 considerations to improve postoperative recovery. *Current pain and headache reports* 2019; **23**: 1-8

296 6 Silver JK, Baima J. Cancer prehabilitation: an opportunity to decrease treatment-related morbidity,  
297 increase cancer treatment options, and improve physical and psychological health outcomes.  
298 *American journal of physical medicine & rehabilitation* 2013; **92**: 715-27

299 7 Adamsen L, Quist M, Andersen C, et al. Effect of a multimodal high intensity exercise intervention  
300 in cancer patients undergoing chemotherapy: randomised controlled trial. *Bmj* 2009; **339**

301 8 Egegaard T, Rohold J, Lillelund C, Persson G, Quist M. Pre-radiotherapy daily exercise training in  
302 non-small cell lung cancer: A feasibility study. *Reports of Practical Oncology and Radiotherapy* 2019;  
303 **24**: 375-82

304 9 Grimmett C, Bates A, West M, et al. SafeFit Trial: virtual clinics to deliver a multimodal intervention  
305 to improve psychological and physical well-being in people with cancer. Protocol of a COVID-19  
306 targeted non-randomised phase III trial. *BMJ open* 2021; **11**: e048175

307 10 Macmillan Cancer Support. Principles and Guidance for Prehabilitation within the Management  
308 and Support of People with Cancer 2020. Available from [https://www.macmillan.org.uk/healthcare-](https://www.macmillan.org.uk/healthcare-professionals/news-and-resources/guides/principles-and-guidance-for-prehabilitation)  
309 [professional/news-and-resources/guides/principles-and-guidance-for-prehabilitation](https://www.macmillan.org.uk/healthcare-professionals/news-and-resources/guides/principles-and-guidance-for-prehabilitation) (accessed 16  
310 January 2024)

311 11 Gillis C, Davies SJ, Carli F, et al. Current Landscape of Nutrition Within Prehabilitation Oncology  
312 Research: A Scoping Review. *Frontiers in Nutrition* 2021; **8**

313 12 Meneses-Echávez JF, González-Jiménez E, Ramírez-Vélez R. Effects of supervised multimodal  
314 exercise interventions on cancer-related fatigue: systematic review and meta-analysis of randomized  
315 controlled trials. *BioMed research international* 2015; **2015**

316 13 Spence RR, Heesch KC, Brown WJ. Exercise and cancer rehabilitation: a systematic review. *Cancer*  
317 *treatment reviews* 2010; **36**: 185-94

318 14 Pritchard MW, Robinson A, Lewis SR, et al. Perioperative exercise programmes to promote  
319 physical activity in the medium to long term: systematic review and qualitative research. 2022; **10**:  
320 21

321 15 Mclsaac DI, Gill M, Boland L, et al. Prehabilitation in adult patients undergoing surgery: an  
322 umbrella review of systematic reviews. *British Journal of Anaesthesia* 2022; **128**: 244-57

323 16 COMET Initiative. Core Outcome Measures in Effectiveness Trials. 2021. Available from  
324 <https://www.comet-initiative.org/> (accessed 16 January 2024)

325 17 Rammant E, Saxton J, Moug S, et al. Prehabilitation outcomes for intra-abdominal cancer  
326 patients: protocol for the development of a core outcome set (COS). 2020

327 18 Pearson I, Blackwell S, Fish R, et al. Defining standards in colorectal optimisation: a Delphi study  
328 protocol to achieve international consensus on key standards for colorectal surgery prehabilitation.  
329 *BMJ open* 2021; **11**: e047235

330 19 Raichurkar P, Denehy L, Solomon M, et al. Research priorities in prehabilitation for patients  
331 undergoing cancer surgery: an international Delphi study. *Annals of surgical oncology* 2023; **30**:  
332 7226-35

333 20 Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for  
334 intervention description and replication (TIDieR) checklist and guide. *Bmj* 2014; **348**

335 21 Slade SC, Dionne CE, Underwood M, et al. Consensus on exercise reporting template (CERT):  
336 modified Delphi study. *Physical therapy* 2016; **96**: 1514-24

337

338

Table 1 Summary of reporting characteristics and outcome measures being captured by ten cancer prehabilitation groups across the United Kingdom, Australia, Canada and Italy.

	Count (%)	Measurement method/tool where applicable
<b>Baseline characteristics</b>		
Age	10 (100%)	
Sex	10 (100%)	
Postcode	10 (100%)	
Ethnicity	7 (70%)	
Education	4 (40%)	
Marital status	2 (20%)	
Employment status	7 (70%)	
<b>Medical history and screening</b>		
General medical history	8 (80%)	
Cancer type	6 (60%)	
Surgery type	3 (30%)	
Cancer stage	3 (30%)	
Nutritional assessment/screening	7 (70%)	PG-SGA, mPG-SGA, MUST, Canadian nutrition screening tool
<b>Objective (physical or physiological) measures</b>		
Blood pressure	9 (90%)	
Resting heart rate	9 (90%)	
Height	10 (100%)	
Body mass	10 (100%)	
Waist girth	4 (40%)	
Hip girth	3 (30%)	
Waist-hip-ratio	3 (30%)	
Aerobic capacity	10 (100%)	CPET, 6MWT
Spirometry	4 (40%)	
Hand grip strength	9 (90%)	Hand grip dynamometer
Leg strength	7 (70%)	Sit to stand test
Accelerometry	1 (10%)	
<b>Self-report (psychological and behavioural) measures</b>		
Physical activity	8 (80%)	EVS, CHAMPS, Active Lives Survey, GLTEQ, IPAQ
Functional status	5 (50%)	DASI
Fatigue	5 (50%)	FACIT-Fatigue, EORTC QLQ-C30 sub-scale
Patient Activation	4 (40%)	PAM
Quality of life	10 (100%)	EQ-5D-5L, EORTC QLQ-C30, SF12
Health and disability	2 (20%)	WHODAS 2.0
Anxiety and depression	7 (70%)	PHQ-9, GAD-7, HADS, major depression inventory
Exercise self-efficacy	3 (30%)	Self-efficacy for exercise scale
Exercise motivation	1 (10%)	BREQ-3
Satisfaction with support	4 (40%)	Family and Friends test, bespoke patient satisfaction survey
<b>Medical record data</b>		
Length of stay	9 (90%)	
Treatment completion rates	5 (50%)	
Cancer recurrence - site and stage	5 (50%)	
Accident and emergency attendance	7 (70%)	



	Count (%)	Measurement method/tool where applicable
Hospital readmissions	8 (80%)	unplanned inpatient less than 3 days/more than three days, 30-day readmission, 90-day readmission
Surgical complications	2 (20%)	Clavien-Dindo
Mortality	8 (80%)	

PG-SGA – Patient-Generated Subjective Global Assessment; mPG-SGA – modified Patient-Generated Subjective Global Assessment; MUST - Malnutrition Universal Screening Tool; CPET - Cardiopulmonary exercise test; 6MWT – 6-minute walk test; EVS – exercise vital signs; CHAMPS – CHAMPS physical activity questionnaire; GLTEQ – Godin Leisure-Time Exercise Questionnaire; IPAQ – International Physical Activity Questionnaire; DASIS – Duke Activity Status Index; FACIT – Functional Assessment of Chronic Illness Therapy; EORTC QLQ-C30 - European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire; PAM – Patient Activation Measure; EQ-5D-5L – European Quality of Life-5 Dimensions-5 Levels; SF12 – 12-Item Short Form Survey; WHODAS 2.0 – World Health Organization Disability Assessment Schedule 2.0; PHQ-9 – Patient Health Questionnaire-9; GAD-7 – General Anxiety Disorder-7; HADS - Hospital Anxiety and Depression Scale; BREQ-3 – Behavioural Regulation in Exercise Questionnaire.